Regencell Bioscience (NASDAQ:RGC) Stock Price Up 8.8% – Should You Buy?

Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s share price rose 8.8% during trading on Friday . The stock traded as high as $28.40 and last traded at $29.2770. Approximately 36,687 shares changed hands during mid-day trading, a decline of 88% from the average daily volume of 318,715 shares. The stock had previously closed at $26.91.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

Regencell Bioscience Price Performance

The company’s 50-day moving average is $27.34 and its 200 day moving average is $24.25.

Regencell Bioscience (NASDAQ:RGC) last announced its quarterly earnings data on Friday, May 8th. The company reported $0.00 EPS for the quarter.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Squarepoint Ops LLC acquired a new position in shares of Regencell Bioscience in the 2nd quarter valued at about $1,701,000. BNP Paribas Financial Markets purchased a new stake in shares of Regencell Bioscience during the second quarter valued at $768,000. XTX Topco Ltd purchased a new stake in shares of Regencell Bioscience during the third quarter valued at $598,000. Hudson Bay Capital Management LP purchased a new stake in shares of Regencell Bioscience during the fourth quarter valued at $275,000. Finally, Vident Advisory LLC lifted its holdings in shares of Regencell Bioscience by 65.7% during the fourth quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after purchasing an additional 11,866 shares during the last quarter. Hedge funds and other institutional investors own 0.13% of the company’s stock.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.